US Patent Battles May Resume Next Congress; Reps Press For IPR Reform

10 New York representatives urge PTO to deny access to the inter partes review process to hedge funds and non-practitioners; generic companies join non-practicing entity Neptune Generics in challenging Lilly’s Almita patent.

While biopharma innovators failed to win major changes to the inter partes review (IPR) patent challenge proceeding this year, several members of the House have indicated that they are willing to continue the battle in the next Congress.

Ten US House Representatives from New York sent a Dec. 5 letter to US Patent and Trademark Office...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet